Pharmacological inhibition of the primary endocannabinoid producing enzyme, DGL-α, induces autism spectrum disorder-like and co-morbid phenotypes in adult C57BL/J mice.
Blocking the brain’s own cannabis chemical in mice copies ASD social and repetitive traits.
01Research in Context
What this study did
Scientists gave adult mice a drug that blocks the enzyme DGL-α. This enzyme makes 2-AG, the main brain endocannabinoid.
They watched how the mice acted with cage-mates and objects. They also scored repetitive movements.
What they found
Mice with less 2-AG spent little time sniffing or following partners. They groomed the same spot over and over.
The pattern looked like core ASD traits: social withdrawal and fixed repetitive behavior.
How this fits with other research
Granieri et al. (2020) saw the same social and repetitive problems, but in rats missing the Cntnap2 gene. Both labs create ASD-like rodents, one with chemistry, one with genetics.
Adak et al. (2021) link two GABA-A gene variants to human ASD risk. William et al. now show the brain’s own cannabis system can trigger similar traits, hinting that both GABA and endocannabinoid paths may feed one behavior circuit.
Barua et al. (2011) found an autism-linked enzyme change that raises brain toxins. The new mouse data add the endocannabinoid system to the growing list of biochemical routes that can nudge behavior toward the ASD zone.
Why it matters
You can’t dose clients with DO34, but you can track new drug trials aimed at ECS tone. If a medicine boosts 2-AG, watch for jumps in social initiation or drops in stereotypy. Share the rodent story with families to explain why balancing brain chemistry—not just behavior—matters.
Get CEUs on This Topic — Free
The ABA Clubhouse has 60+ on-demand CEUs including ethics, supervision, and clinical topics like this one. Plus a new live CEU every Wednesday.
Add ‘endocannabinoid’ to your literature-watch list and note any ECS drugs entering human trials.
02At a glance
03Original abstract
Accumulating evidence links dysfunction in the endocannabinoid system (ECS) with the pathology of neurodevelopmental disorders, particularly autism spectrum disorder (ASD). Variants in ECS genes CNR1 and DAGLA are associated with neurological phenotypes in humans. The endocannabinoids (eCBs), 2-AG and AEA, which act at the primary cannabinoid receptor (CB1), mediate behaviors relevant to neurodevelopmental disorders. The overlap between these eCBs is poorly understood. Most ECS studies have focused on stress responses, anxiety, and epilepsy, however, its role in social behavior and communication has only recently come under investigation. This represents a critical gap in our understanding of the ECS and its relationship to ASD. Furthermore, the increasing prevalence of ASD and a lack of therapeutics emphasize a crucial need for novel therapeutic targets. To this aim, we used an inhibitor of the eCB producing enzyme DGL-α, DO34, and the CB1 inverse agonist, rimonabant, to evaluate the role of the primary eCB, 2-AG, in ASD. Adult male C57BL/6J mice were used in a series of behavioral paradigms which assessed social behavior, social communication, repetitive behaviors, anxiety and locomotor activity. DO34 and rimonabant increased anxiety-like behavior, while only DO34 induced hyperactivity, social deficits, and repetitive self-grooming behavior. These data indicate that reduced 2-AG bioavailability, or CB1 inhibition, each induce unique respective behavioral phenotypes relevant to neurodevelopmental disorders, particularly ASD. This suggests fundamental differences in CB1 signaling via 2-AG and the CB1 receptor itself, particularly for social behaviors, and that 2-AG signaling may represent a target for the development of novel therapeutics. LAY SUMMARY: Endocannabinoids play a critical role in the developing nervous system. Alterations in the endocannabinoid system are linked to neurodevelopmental disorders. Studies suggest these variants may play a critical role in the core symptoms of autism spectrum disorder. In this study, pharmacological inhibition of the primary endocannabinoid producing enzyme, DGL-α, induced a constellation of deficits in behavioral domains associated with autism.
Autism research : official journal of the International Society for Autism Research, 2021 · doi:10.1002/aur.2520